Israel

AI Citation Summary

• Country: Israel
• Product line: Medical devices
• Regulator / source: Market Characteristics: A high-technology medical market with high per capita healthcare expenditure; a significant proportion of private hospitals and outpatient clinics; strong demand for innovative medical devices; a well-developed domestic medical technology industry (numerous startups and multinational R&D centers); regulatory quality aligned with Europe and the United States
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: 4. AMAR reviews document completeness (approximately 1–2 months); may issue a Deficiency Letter
• Key fees: Regulatory route - Which product category, risk class, application type, reliance route, or special pathway applies? - Confirm the pathway before translating the dossier; route choice drives evidence, timing, fees, inspections, labelling, and change-control obligations
• Local requirement: Israel medical-device entry should be separated into Israel Ministry of Health AMAR regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Market Overview

• Population: Approximately 9.5 million (2024)
• Healthcare System: Universal mandatory health insurance (the Kupot Holim system — four major health funds: Clalit, Maccabi, Meuhedet, Leumit), with coexisting public and private sectors and extremely high coverage rates
• Market Characteristics: A high-technology medical market with high per capita healthcare expenditure; a significant proportion of private hospitals and outpatient clinics; strong demand for innovative medical devices; a well-developed domestic medical technology industry (numerous startups and multinational R&D centers); regulatory quality aligned with Europe and the United States
• Regulatory Maturity: Highly mature; the regulatory framework is benchmarked against EU MDR; broadly recognizes FDA 510(k)/PMA and EU CE marking as reference market approvals

Market-Entry Logic

Israel medical-device entry should be separated into Israel Ministry of Health AMAR regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.

Entry layer	Key question	Practical view
Regulatory route	Which product category, risk class, application type, reliance route, or special pathway applies?	Confirm the pathway before translating the dossier; route choice drives evidence, timing, fees, inspections, labelling, and change-control obligations
Local execution	Who holds the registration, imports, answers regulator questions, manages safety reporting, and controls renewals or variations?	Contract structure matters because local agents, sponsors, distributors, or licence holders can control practical market access even when the foreign manufacturer owns the product
Evidence and economics	What clinical, quality, performance, HTA, pricing, and budget-impact evidence is needed?	Registration evidence and payer evidence should be planned together; otherwise approval may be achieved without reimbursement, tender access, or hospital adoption
Channel access	Which payer, hospital, distributor, retail, tender, or private-care channel will create volume?	Start with the channel that matches product value and service burden; premium products often need reference sites before broad tender or retail expansion

Main Players and Channel Map

Type	Representative players	Market meaning
Regulator / review	Israel Ministry of Health AMAR	Determines approval route, technical evidence, inspections, labelling, post-market duties, renewals, and variations
Payment / procurement	health funds / HMOs, Ministry of Health basket committee, hospitals and private insurers	Determines reimbursement, tender economics, price ceilings, purchasing lists, and patient affordability
Companies / channels	Medtronic, Philips, GE HealthCare, Siemens Healthineers, local startups, Sheba, Hadassah, Ichilov and HMO procurement channels	Shows the competitive set, partner universe, distribution power, hospital access points, and local execution benchmarks
End users / buyers	Public hospitals, private hospital groups, specialist centers, laboratories, pharmacies, insurers, and regional distributors	Determine adoption, tender volume, reference cases, service expectations, and receivables risk

Development Trends

1. Approval and access are increasingly separate: Technical approval does not guarantee reimbursement, procurement listing, physician adoption, or patient affordability.
2. Local execution quality is a major differentiator: Strong local regulatory, medical, market-access, distribution, and service teams reduce deficiency, launch, and lifecycle risk.
3. Evidence expectations are rising: Payers and hospitals increasingly ask for comparative clinical value, real-world evidence, budget impact, and operational service data.
4. Pricing pressure is structural: reference-country reliance, health basket access, strong digital-health ecosystem, HMO purchasing power, security logistics and startup partnership opportunities are reshaping launch sequencing and product economics.
5. Partner control should be managed early: Contracts should protect dossier access, registration ownership, renewal obligations, safety reporting, inventory, and transition rights.

Regulatory Authority

• Competent Authority: Ministry of Health of Israel (MOH / משרד הבריאות), through the Medical Technology, Cosmetics and Non-Ionizing Radiation Division (MTCNIR); specific registration matters are handled by AMAR (Agaf Meizug Rishum / אגף מאיזון רישום — the Medical Device Registration Directorate)
• Official Portal: https://www.health.gov.il/English/Topics/MedicalEquipment/Pages/default.aspx (English); AMAR online submission system: https://amar.health.gov.il
• Key Regulations:
  • Medical Devices Law 5772-2012
  • Medical Devices Regulations 5774-2014
  • MOH Circulars / Director General Circulars: continuously updated technical requirements
  • IVDs are separately regulated under the In Vitro Diagnostic Devices Regulations

Device Classification System

Local Class	Risk Level	EU/FDA Equivalent	Description
Class 1	Low risk	EU Class I / FDA Class I	General devices; some exempt from registration
Class 2	Low-medium risk	EU Class IIa / FDA Class II	Registration required; eligible for reference market fast-track pathway
Class 3	Medium-high risk	EU Class IIb / FDA Class II–III	Full technical review required; may leverage reference market approvals
Class 4	High risk	EU Class III / FDA Class III (PMA)	Highest review level; strong clinical evidence required

IVDs have an independent classification system, divided into Classes A/B/C/D following the EU IVDR framework.

Registration Pathways

Pathway for Foreign Manufacturers

Pathway 1: Reference Market Accelerated Pathway (Recommended — Preferred for Class 2–4)

1. Obtain reference market approval documents (FDA 510(k)/De Novo/PMA or EU CE Certificate under MDD/MDR)
2. Appoint a licensed Israeli Authorized Representative (IAR / נציג מורשה) in Israel
3. Submit a registration application through the AMAR online portal, attaching reference market approval documents, a Technical File summary, and draft Hebrew-language labeling
4. AMAR reviews document completeness (approximately 1–2 months); may issue a Deficiency Letter
5. Technical review (substantially simplified under the reference market pathway, primarily verifying differences)
6. Obtain registration certificate (Approval of Medical Devices, AMAR Certificate)

Pathway 2: Full Technical Assessment Pathway (No Reference Market Approval — Class 1 Exemption or Novel Devices)

1. Appoint an IAR
2. Prepare a complete Technical File (comparable to EU MDR Technical Documentation)
3. Submit through the AMAR portal, including a Clinical Evaluation Report, Risk Management documentation, and performance and safety test reports
4. AMAR may commission external expert review (especially for Class 3–4)
5. Supplementary information rounds (typically 1–3 rounds)
6. Obtain registration certificate

Pathway 3: Class 1 Exemption / Notification

Certain Class 1 non-sterile, non-measuring devices may apply for registration exemption and only require notification, with no full review necessary.

Key Prerequisites

• A licensed IAR (a legal entity or natural person registered in Israel; must apply for authorized qualifications from MOH) is mandatory
• Reference market documents must be currently valid official approvals (CE certificates must be from a Notified Body; revoked or expired certificates are not accepted)
• All documents must be provided in English; AMAR does not mandate Hebrew-language technical files, but labeling must be in Hebrew
• IVD devices must meet additional performance verification requirements; local confirmatory testing in Israel may be required in some cases

Registration Dossier Requirements

• ISO 13485 certificate (issued by an accredited body, within validity period)
• Free Sale Certificate (FSC / Certificate of Free Sale), must be authenticated by the Israeli Embassy in the country of origin or Apostilled
• Reference market approval documents (FDA 510(k) Decision Letter or EU CE Certificate + Declaration of Conformity)
• Product description and intended purpose (English)
• Device classification justification
• Risk management summary (compliant with ISO 14971)
• Clinical Evaluation Report (Class 2–4; under the reference market pathway, the corresponding clinical summary from the reference market may be submitted)
• Performance/safety test reports (electrical safety, biocompatibility, etc., per IEC/ISO standards)
• Instructions for Use (IFU) in Hebrew (mandatory) + English
• Draft labeling (primarily Hebrew; English may appear alongside)
• IAR Letter of Authorization (LOA)
• Manufacturer information (factory address, QMS overview)
• IVD additional: analytical performance data, reference interval data (if applicable to the Israeli population)

Registration Timelines

Stage	Official Target	Practical Reference
Reference market fast-track (Class 2–3)	90 days (official target)	3–6 months (when documents are complete)
Reference market fast-track (Class 4)	180 days	6–12 months
Full technical assessment pathway (Class 2–3)	180 days	9–18 months
Full technical assessment pathway (Class 4)	365 days	18–30 months
Class 1 exemption notification	30 days	1–2 months
Supplementary information response wait (per round)	—	Additional 2–4 months per round

Practical Note: AMAR experiences review backlogs during peak periods; office working hours are effectively shorter around Jewish holidays (Rosh Hashana, Yom Kippur, etc.) — allow buffer time when planning.

Registration Fees

Item	Estimated Cost (USD)
AMAR official registration fee (Class 1)	$200–$500
AMAR official registration fee (Class 2–3)	$500–$1,500
AMAR official registration fee (Class 4)	$1,500–$3,000
IAR annual service fee (Authorized Representative)	$3,000–$8,000/year
Regulatory consulting / document preparation (external consultant)	$5,000–$20,000 (depending on complexity)
Document notarization / Apostille fees	$300–$800
Hebrew translation (labeling + IFU)	$1,000–$3,000
Certificate maintenance annual fee (AMAR)	$300–$1,000/year

Total market entry cost (Class 2, reference market pathway): USD 10,000–30,000; Class 4 full review pathway can reach USD 30,000–60,000+

Local Representative Requirements

• Mandatory: Yes — an Israeli Authorized Representative (IAR) must be legally appointed
• Representative Qualifications: Must be registered with the Israeli MOH as an authorized representative; must possess medical device regulatory knowledge and bear legal responsibility for post-market regulatory obligations (adverse event reporting, recall coordination, etc.)
• Registration Certificate Holder Rules: The registration certificate is typically issued in the manufacturer's name, with the IAR serving as the legally mandated contact and responsible party; IAR changes must be reported to AMAR and the registration file updated

Import Requirements

• Import Permit: No separate import permit is required; the AMAR registration certificate serves as the marketing authorization; the first imported batch must submit import customs declarations and a copy of the AMAR registration certificate
• Customs Requirements: Israel Customs Authority requires HS code declaration; certain devices (radiation-emitting, laser devices) require additional licenses from the MOH Radiation Authority
• Labeling Language: Hebrew is mandatory; English may appear alongside; outer packaging and IFU must contain Hebrew content — English-only labeling is non-compliant

Post-Market Surveillance

• Adverse Event Reporting: The manufacturer/IAR must report serious adverse events to AMAR within 10 working days (serious injury/death) or 30 days (other serious adverse events) of becoming aware; timelines are broadly aligned with EU MDR
• Recall Rules: The IAR must cooperate with MOH in executing recalls; recall reports must be submitted through the AMAR portal; Field Safety Corrective Actions (FSCAs) must be simultaneously notified to AMAR
• Periodic Safety Reports: Class 3–4 devices must periodically submit Post-Market Clinical Follow-Up (PMCF) updates and safety summary reports; frequency follows EU MDR requirements (annually or biannually)

Renewal Requirements

• Certificate Validity: Typically 5 years (some categories 3 years, as noted on the AMAR-issued certificate)
• Renewal Timeline: Submit the renewal application at least 6 months before expiry (initiate preparation 9 months in advance to avoid supplementary information delays); sales may continue during the renewal period if an application has been submitted

Special Regulatory Requirements

• UDI: Israel is progressively introducing UDI requirements, following EU MDR UDI rules; Class 3–4 devices already face mandatory requirements; the Class 1–2 roadmap is continuously being updated — it is advisable to plan GS1/HIBCC UDI registration in advance
• Local Testing: Local testing is generally not mandatorily required; however, for certain IVDs or high-risk devices, AMAR may require confirmatory testing at Israeli-accredited laboratories; electromagnetic compatibility (EMC) must comply with Ministry of Communications (MOC) standards
• Special Category Restrictions: Devices incorporating radiation sources require additional authorization from MOH's Radiation and Nuclear Safety Authority (RNSA); CIEDs (Cardiovascular Implantable Electronic Devices), neuromodulation devices, and other high-risk categories are subject to stricter review; Software as a Medical Device (SaMD) is treated per EU MDR Software rules, and software lifecycle documentation must be provided

Market Access Channels

• Public Hospital Procurement: Through centralized procurement by the four major Kupot Holim health funds (Clalit is the largest, covering approximately 56% of the population); government hospitals (Ichilov/Tel Aviv Sourasky, Hadassah, Sheba, etc.) each have procurement committees; innovative devices may apply to health fund Technology Assessment Committees for "new technology" evaluation
• Private Hospitals/Clinics: Private medical institutions (Assuta, Herzliya Medical Center, etc.) have more flexible procurement autonomy and relatively lower entry barriers — suitable for premium/innovative devices to enter the market first
• Distribution/E-commerce: B2B distribution through licensed local distributors; consumer medical devices can be sold through retail channels (pharmacies, medical device specialty stores), ensuring retail labeling compliance
• Government Tenders: MOH centralized tendering (Central Purchasing Unit); participation requires a local registered agent; price competition is intense

Market Entry Strategy Recommendations

• Recommended Pathway: Manufacturers holding FDA 510(k) or EU CE (especially MDR certificates) should prioritize the reference market accelerated pathway, compressing the total registration timeline to 3–6 months; if holding only MDD CE (legacy), it is advisable to simultaneously advance MDR transition to ensure Israeli acceptance
• Key Risks:
  1. Hebrew labeling is a high-frequency failure point — translation errors or format non-compliance cause entire batches to be rejected; engage professional medical translators
  2. IAR changes involve complex procedures; select the IAR carefully, assessing regulatory qualifications and service capability
  3. AMAR backlogs are most pronounced around Jewish holidays (Rosh Hashana, Yom Kippur); avoid submitting during these periods
  4. IVD special requirements: Some IVDs require local performance confirmation; discuss in advance with AMAR whether Israeli clinical data is needed
• Practical Tips:
  • Engage an Israeli local regulatory affairs consultant (RA Consultant) familiar with the AMAR system to assist with document preparation; their communication efficiency with AMAR reviewers far exceeds that of overseas consultants
  • Entering the Health Technology Assessment (HTA) process of Clalit/Maccabi requires health economics evidence; manufacturers of high-value devices should prepare cost-effectiveness analyses in advance
  • Israel's medical market has high openness to innovative technology; academic centers (Sheba, Hadassah) have strong willingness to engage in clinical research — consider entering the market through clinical research first (requires applying to AMAR for IDE-equivalent authorization)

Impact of Existing CE / FDA / NMPA Certificates

Quick Assessment

Certificate	Acceleration Effect	Key Mechanism
EU CE (MDR/IVDR)	⭐⭐⭐⭐⭐	AMAR has a formal "Reference Market Fast-Track Review" pathway; CE can compress the approval timeline from 9–30 months to 3–6 months
US FDA (510(k)/PMA)	⭐⭐⭐⭐⭐	FDA approval carries the highest weight in the reference market pathway; AMAR reviewers directly accept FDA documents as technical evidence without independent technical re-assessment
China NMPA	⭐	Israel does not recognize NMPA; no formal acceleration mechanism; must follow the full technical review pathway

EU CE (MDR/MDD/IVDR)

• Recognition Mechanism: The Israeli MOH's AMAR has established a formal "Reference Market Accelerated Review" pathway. Class 2–4 devices holding a CE certificate issued by an EU Notified Body (under either MDR or MDD, though MDR carries higher recognition) are eligible to apply for the reference market fast-track pathway. Under this pathway, AMAR does not independently re-conduct a full technical assessment; instead, it uses the Technical File corresponding to the CE certificate as the basis, verifying product compliance and Israel-specific requirements (primarily Hebrew labeling compliance and local Authorized Representative arrangement).
• Actual Effect: This is the market in the Middle East where CE and FDA acceleration effects are most pronounced and most quantifiable. Class 2–3 devices with a valid CE certificate can realistically compress the review timeline to 3–6 months (official target: 90 days), compared to 9–18 months for the same products without CE requiring full review; Class 4 devices with CE take approximately 6–12 months, versus 18–30 months without CE. The overall review acceleration effect represents approximately a 60%–70% reduction in timeline — the most direct and quantifiable value for manufacturers.
• Key Caveats: The CE certificate must be issued by an EU-recognized Notified Body; expired or revoked certificates are not accepted; if the CE certificate is based on MDD (legacy), AMAR accepts it but may require a supplementary statement on the MDR transition plan; the CE Declaration of Conformity (DoC) must be submitted alongside the certificate; if the product has indications or model variations beyond the CE-approved scope, additional explanation is required; Hebrew labeling and IFU are mandatory Israel-specific requirements that must be independently prepared and are unrelated to CE certification.

US FDA (510(k) / De Novo / PMA)

• Recognition Mechanism: FDA approval (510(k) Decision Letter, De Novo Grant Order, PMA Order) carries the highest weight in Israel's reference market pathway — equal to or even greater accelerating effect than CE certificates. AMAR treats FDA approval as the highest level of external validation of product safety and efficacy; under the reference market pathway, AMAR reviewers directly accept FDA technical documentation (including 510(k) Summaries and PMA Summaries of Safety and Effectiveness Data) as technical evidence without independently re-conducting technical assessment.
• Actual Effect: Class 4 devices with FDA PMA approval can compress the Israeli review timeline to 6–9 months; Class 2–3 devices with FDA 510(k) have a realistic review timeline of approximately 3–5 months. FDA + CE dual certification is the optimal combination for Israel market entry, maximizing reduction of AMAR supplementary information rounds and accelerating AMAR's internal review scheduling.
• Key Caveats: FDA documents must be currently valid (withdrawn 510(k)s are not accepted); if special controls or PMA conditions apply after FDA approval, compliance with these must be explained to AMAR; the indications covered by the FDA approval and the intended purpose in the Israeli application must be consistent — differences must be explained in writing; IVD devices typically must simultaneously meet FDA approval requirements and Israeli local performance verification (if deemed necessary by AMAR).

China NMPA (National Medical Products Administration)

• Recognition Mechanism: AMAR does not list China's NMPA as a reference market; NMPA certificates cannot trigger the reference market fast-track review pathway. Although Israel and China have certain cooperation in the technology sector (including some medical technology MOUs), there has been no substantive progress at the regulatory mutual recognition level; NMPA approvals carry no formal exemption effect in AMAR reviews.
• Actual Effect: No formal acceleration effect. Chinese manufacturers holding only NMPA certificates must follow the full technical review pathway (Class 2–3: 9–18 months; Class 4: 18–30 months), at the same review intensity as products with no foreign approvals. NMPA certificates may be submitted as an "international marketing history" attachment, but do not produce a pathway difference.
• Key Caveats: The core strategy for Chinese manufacturers entering the Israeli market is to first obtain EU CE certification (especially MDR certificates) as the key to triggering AMAR's fast-track review pathway; given that Israel is the Middle East market where CE/FDA acceleration effects are most pronounced and most quantifiable, the strategic return on this regulatory investment is extremely high.

Practical Recommendations

1. CE/FDA is a strategic asset for entering the Israeli market: Israel is the market in the Middle East where recognition of CE and FDA is highest and acceleration effects are most quantifiable; manufacturers holding CE or FDA should prioritize Israel as a target market — short registration timelines and high certainty
2. Hebrew compliance must be planned in advance: Hebrew labeling and IFU are unique Israeli requirements; translation errors are the most frequent review failure point — engage an Israeli local translation agency with a medical device professional background, and have the IAR conduct final review before submission
3. IAR selection is critically important: The licensed IAR (Israeli Authorized Representative) is not only a legal requirement; their day-to-day working relationship with AMAR and proficiency in system operations directly affect review progress and supplementary information communication efficiency — selecting an IAR with extensive AMAR system experience is a key success factor for entering the Israeli market
4. Israel can serve as a technical validation node for the MENA market: Israeli academic medical centers (Sheba, Hadassah, etc.) have extremely high openness to innovative devices — entering first through clinical research can accumulate Israeli clinical data as supplementary evidence for CE/FDA applications, while simultaneously establishing a commercial foothold in the Israeli market
5. Jewish holiday timing considerations: AMAR's review progress noticeably slows around major Jewish holidays (Rosh Hashana, Yom Kippur, Passover); submission timing should avoid the main holiday seasons (typically September and April) to reduce unnecessary waiting